Pulmonary toxicity due to chemotherapy. How is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?

Internal Medicine

Volumn 42, Issue 10, 2003, Pages 926-927

  Okamoto, Isamu ^a   Suga, Moritaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Pulmonary toxicity; ZD1839 (Iressa)

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; GEMCITABINE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACUTE RESPIRATORY FAILURE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDITORIAL; HUMAN; IATROGENIC DISEASE; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LUNG TUMOR; RASH; RISK BENEFIT ANALYSIS; THORAX RADIOGRAPHY;

EID: 0242606878     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.926     Document Type: Editorial

References (12)

1. Maniwa K, Tanaka E, Inoue T, et al. An autopsy case of acute pulmonary toxicity associated with gemcitabine. Intern Med 42: 1022-1025, 2003.
2. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage - the role of oxygen, shock, and related factors. Am J Pathol 85: 209-228, 1976.
3. Blennerhassett JB. Shock lung and diffuse alveolar damage pathological and pathogenetic considerations. Pathology 17: 239-247, 1985.
4. Gupta N, Ahmed I, Steinberg H, et al. Gemcitabine-induced pulmonary toxicity. Case report and review of the literature. Am J Clin Oncol 25: 96-100, 2002.
5. Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 20: 311-315, 2002.
6. Ichikado K, Suga M, Muller NL, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 165: 1551-1556, 2002.
7. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139, 2003.
8. Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40: 339-342, 2003.
9. Hama R, Sakaguchi K. The gefitinib story. ISDB Newsletter 17: 6-9, 2003.
10. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13: 491-498, 2001.
11. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
12. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292a, 2002.